medwireNews: The European Commission has approved guselkumab, a monoclonal antibody targeting interleukin (IL)-23, for the treatment of psoriatic arthritis (PsA).
Previously approved for the treatment of moderate-to-severe plaque psoriasis, guselkumab may now be used alone or in combination with methotrexate for the treatment of PsA in adults with an inadequate response or intolerance to prior DMARD therapy.
This approval is based on the results of the DISCOVER-1 and DISCOVER-2 trials, which demonstrated significantly better clinical and radiographic outcomes among PsA patients treated with the IL-23 inhibitor compared with those given placebo.
The European announcement follows the US FDA approval of guselkumab for PsA in July 2020.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group